How immune cells are activated Research PSI A research consortium has deciphered the mechanism of CCR5 receptor activation, providing insights for the development of CCR5 drug antagonists for AIDS, cancer, and inflammatory diseases. They build proteins that are not known to nature TechTransfer ETH Zurich Using chemical synthesis, Bright Peak Therapeutics can produce proteins that have never before existed. This holds great potential for cancer immunotherapy. The Basel-based spin-off has its beginnings at ETH Zurich. Previous 31 32 33 34 35 36 37 38 Page 38 of 38
